[
  {
    "ts": null,
    "headline": "Barclays Raises Johnson & Johnson (JNJ) Price Target After Updated Estimates",
    "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 15 Dividend Stocks that Outperform the S&P 500. Barclays lifted its price⁠ tar⁠g⁠et o⁠n Johnson & Johnson (NYSE:JNJ) to $197 from $176​ on December 2 while maintaining an E‌qua‌l Weight rating. Th‍e fi‍rm als​o refreshe⁠d its‌ estimates for the compan⁠y. Johnson & Johnson (NYSE:JNJ) continues t⁠o⁠ b‌enefit […]",
    "url": "https://finnhub.io/api/news?id=08790aa7f70a014636a68d7cada7fbae9005c4574cbc09d4db34ad7df07c9d88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764791097,
      "headline": "Barclays Raises Johnson & Johnson (JNJ) Price Target After Updated Estimates",
      "id": 137677757,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 15 Dividend Stocks that Outperform the S&P 500. Barclays lifted its price⁠ tar⁠g⁠et o⁠n Johnson & Johnson (NYSE:JNJ) to $197 from $176​ on December 2 while maintaining an E‌qua‌l Weight rating. Th‍e fi‍rm als​o refreshe⁠d its‌ estimates for the compan⁠y. Johnson & Johnson (NYSE:JNJ) continues t⁠o⁠ b‌enefit […]",
      "url": "https://finnhub.io/api/news?id=08790aa7f70a014636a68d7cada7fbae9005c4574cbc09d4db34ad7df07c9d88"
    }
  },
  {
    "ts": null,
    "headline": "Acquisition through growth: The shift in logistics growth strategies",
    "summary": "Neace Ventures’ acquisition of J&J Transportation Consultants and Thoroughbred Transportation may have flown under the radar when it was announced earlier this year, but it represents something much larger happening across the logistics industry. The Louisville-based private investment firm, traditionally known for its holdings in food, beverage, and consumer brands, has been steadily building out […] The post Acquisition through growth: The shift in logistics growth strategies appeared first on",
    "url": "https://finnhub.io/api/news?id=71e7187c390650cc39ca455640b75bd72962521aeb22486db840bf261ccfceae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764789209,
      "headline": "Acquisition through growth: The shift in logistics growth strategies",
      "id": 137677758,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Neace Ventures’ acquisition of J&J Transportation Consultants and Thoroughbred Transportation may have flown under the radar when it was announced earlier this year, but it represents something much larger happening across the logistics industry. The Louisville-based private investment firm, traditionally known for its holdings in food, beverage, and consumer brands, has been steadily building out […] The post Acquisition through growth: The shift in logistics growth strategies appeared first on",
      "url": "https://finnhub.io/api/news?id=71e7187c390650cc39ca455640b75bd72962521aeb22486db840bf261ccfceae"
    }
  },
  {
    "ts": null,
    "headline": "Bayer Stock Up as Government Backs Supreme Court Review in Roundup Case",
    "summary": "Bayer shares jump after the U.S. Solicitor General backs a Supreme Court review of its Roundup case, adding momentum to its strong 2025 run.",
    "url": "https://finnhub.io/api/news?id=021b40bf241b616ffd3f0914aa90fabc9ac20235a955d1cf3f147eff5df90573",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764783660,
      "headline": "Bayer Stock Up as Government Backs Supreme Court Review in Roundup Case",
      "id": 137677759,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Bayer shares jump after the U.S. Solicitor General backs a Supreme Court review of its Roundup case, adding momentum to its strong 2025 run.",
      "url": "https://finnhub.io/api/news?id=021b40bf241b616ffd3f0914aa90fabc9ac20235a955d1cf3f147eff5df90573"
    }
  },
  {
    "ts": null,
    "headline": "Intraocular Lens Market Competitor Analysis Report 2025: Recent Developments, Strategy, Sustainability Benchmarking, Product Launch, Key Persons and Revenue",
    "summary": "The intraocular lens (IOL) market is projected to grow from US$ 4.46 billion in 2024 to US$ 7.16 billion by 2033, reflecting a CAGR of 5.41%. This booming industry is driven by the rising prevalence of cataracts and an aging population, alongside technological advancements in lens solutions such as multifocal and toric lenses. Major players like Novartis, Johnson & Johnson, and Alcon are spearheading innovations to enhance visual outcomes and meet global market demands, particularly in emerging",
    "url": "https://finnhub.io/api/news?id=ae24417790979af293bd64485a7239c1347d1e5e67a219547c883962d7cbce32",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764778320,
      "headline": "Intraocular Lens Market Competitor Analysis Report 2025: Recent Developments, Strategy, Sustainability Benchmarking, Product Launch, Key Persons and Revenue",
      "id": 137672738,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The intraocular lens (IOL) market is projected to grow from US$ 4.46 billion in 2024 to US$ 7.16 billion by 2033, reflecting a CAGR of 5.41%. This booming industry is driven by the rising prevalence of cataracts and an aging population, alongside technological advancements in lens solutions such as multifocal and toric lenses. Major players like Novartis, Johnson & Johnson, and Alcon are spearheading innovations to enhance visual outcomes and meet global market demands, particularly in emerging",
      "url": "https://finnhub.io/api/news?id=ae24417790979af293bd64485a7239c1347d1e5e67a219547c883962d7cbce32"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript",
    "summary": "Johnson & Johnson (JNJ) Citi Annual Global Healthcare Conference 2025 December 3, 2025 11:15 AM ESTCompany ParticipantsMichael Bodner - Global Head of...",
    "url": "https://finnhub.io/api/news?id=23b0d8a44ccf447a100677991adce9d8133ef77d4861e4196ed5cdf0224ea509",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764771205,
      "headline": "Johnson & Johnson (JNJ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript",
      "id": 137673874,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson (JNJ) Citi Annual Global Healthcare Conference 2025 December 3, 2025 11:15 AM ESTCompany ParticipantsMichael Bodner - Global Head of...",
      "url": "https://finnhub.io/api/news?id=23b0d8a44ccf447a100677991adce9d8133ef77d4861e4196ed5cdf0224ea509"
    }
  },
  {
    "ts": null,
    "headline": "Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?",
    "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=71ef7d5c05d89b4f014d85f793d8a8ee57d11e53309cfe15f2e644d29e83dc47",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764770405,
      "headline": "Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?",
      "id": 137671003,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=71ef7d5c05d89b4f014d85f793d8a8ee57d11e53309cfe15f2e644d29e83dc47"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40",
    "summary": "Johnson & Johnson (NYSE: JNJ) – Johnson & Johnson, a global leader in eye health, has partnered with Academy Award–nominated actress, producer, and entrepreneur, Naomi Watts, to change the conversation about vision. Together, they'll encourage simple, practical steps—such as routine eye checks and reframing eye care as part of holistic healthy aging, so that it becomes an easy and empowering part of daily self-care.",
    "url": "https://finnhub.io/api/news?id=3079a62f90628261a549bbe5ce43da9577a2f40a988ca31c4b39d964a40bbcd1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764766800,
      "headline": "Johnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40",
      "id": 137671004,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) – Johnson & Johnson, a global leader in eye health, has partnered with Academy Award–nominated actress, producer, and entrepreneur, Naomi Watts, to change the conversation about vision. Together, they'll encourage simple, practical steps—such as routine eye checks and reframing eye care as part of holistic healthy aging, so that it becomes an easy and empowering part of daily self-care.",
      "url": "https://finnhub.io/api/news?id=3079a62f90628261a549bbe5ce43da9577a2f40a988ca31c4b39d964a40bbcd1"
    }
  },
  {
    "ts": null,
    "headline": "Buy Verizon, December's Ideal \"Safer\" Dog Of The Dow",
    "summary": "Read the latest Dogs of the Dow update: see which top dividend stocks offer optimal value, growth forecasts, and safe yields.",
    "url": "https://finnhub.io/api/news?id=2667faafae3ff28b914df962f1f36c6af7bda25b202492689598e8cf884cc067",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764763343,
      "headline": "Buy Verizon, December's Ideal \"Safer\" Dog Of The Dow",
      "id": 137672165,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219303612/image_1219303612.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Read the latest Dogs of the Dow update: see which top dividend stocks offer optimal value, growth forecasts, and safe yields.",
      "url": "https://finnhub.io/api/news?id=2667faafae3ff28b914df962f1f36c6af7bda25b202492689598e8cf884cc067"
    }
  },
  {
    "ts": null,
    "headline": "Janux Therapeutics: Downgrading To \"Hold\" Rating After Latest Updated Phase 1 JANX007 mCRPC Data",
    "summary": "Janux Therapeutics (JANX) stock is downgraded to Hold after trial setbacks. Read what this means for investors and key upcoming catalysts.",
    "url": "https://finnhub.io/api/news?id=b7fdceddfb70bd2e34b59cd7e9bd0b3d50ebdcaa5e285f8f65e6ded6887f9fc0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764757327,
      "headline": "Janux Therapeutics: Downgrading To \"Hold\" Rating After Latest Updated Phase 1 JANX007 mCRPC Data",
      "id": 137670802,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2240114022/image_2240114022.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Janux Therapeutics (JANX) stock is downgraded to Hold after trial setbacks. Read what this means for investors and key upcoming catalysts.",
      "url": "https://finnhub.io/api/news?id=b7fdceddfb70bd2e34b59cd7e9bd0b3d50ebdcaa5e285f8f65e6ded6887f9fc0"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson’s (JNJ) Multiple Myeloma Breakthrough Drives Buy Rating From Guggenheim",
    "summary": "Johnson & Johnson (NYSE:JNJ) ranks among the Best Low Volatility Investments in December 2025. On November 25, Guggenheim reaffirmed a Buy rating and $206 price target on healthcare giant Johnson & Johnson (NYSE:JNJ), citing favorable clinical trial findings for its multiple myeloma therapy. The firm noted preliminary data from the MajesTEC-3 trial, which combines Johnson […]",
    "url": "https://finnhub.io/api/news?id=6d9cb6b05253b374a2b7a39f57e6f9d8f9e84d82c4e3c20b80305ba43b46a798",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764745058,
      "headline": "Johnson & Johnson’s (JNJ) Multiple Myeloma Breakthrough Drives Buy Rating From Guggenheim",
      "id": 137667583,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) ranks among the Best Low Volatility Investments in December 2025. On November 25, Guggenheim reaffirmed a Buy rating and $206 price target on healthcare giant Johnson & Johnson (NYSE:JNJ), citing favorable clinical trial findings for its multiple myeloma therapy. The firm noted preliminary data from the MajesTEC-3 trial, which combines Johnson […]",
      "url": "https://finnhub.io/api/news?id=6d9cb6b05253b374a2b7a39f57e6f9d8f9e84d82c4e3c20b80305ba43b46a798"
    }
  },
  {
    "ts": null,
    "headline": "Barclays Maintains Johnson & Johnson (JNJ) Equal-Weight Recommendation",
    "summary": "Barclays Maintains Johnson & Johnson (JNJ) Equal-Weight Recommendation",
    "url": "https://finnhub.io/api/news?id=51555c4adf139fe9975c0cd3dfe8363d034dcc31f7aadbcd52a28dfdf04eefbe",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764720334,
      "headline": "Barclays Maintains Johnson & Johnson (JNJ) Equal-Weight Recommendation",
      "id": 137665450,
      "image": "",
      "related": "JNJ",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=51555c4adf139fe9975c0cd3dfe8363d034dcc31f7aadbcd52a28dfdf04eefbe"
    }
  }
]